WAAG
VVOS icon

Wealth Alliance Advisory Group’s Vivos Therapeutics VVOS Stock Holding History

Wealth Alliance Advisory Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-700
Closed -$5.97K – 183
2023
Q1 		$5.97K Sell
700
-350
-33% -$7.66K ﹤0.01% 164
2022
Q4 		$10.6K Sell
1,050
-350
-25% -$5.12K ﹤0.01% 170
2022
Q3 		$23K Buy
+1,400
New +$42.6K 0.01% 155

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wealth Alliance Advisory Group's VVOS Position: Q2 2023 in Review

Wealth Alliance Advisory Group sold out of Vivos Therapeutics (VVOS) in Q2 2023, closing a stake of 700 shares — an estimated $5.97K sold.

Wealth Alliance Advisory Group first reported a position in VVOS in Q3 2022 and held it in 3 quarters. The position peaked at $23K in Q3 2022. 30 funds tracked by Wall St. Rank hold VVOS as of Q2 2023.

  • Wealth Alliance Advisory Group reported no remaining Vivos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Wealth Alliance Advisory Group sold 700 Vivos Therapeutics shares in Q2 2023, an estimated $5.97K.
  • Wealth Alliance Advisory Group first reported a position in Vivos Therapeutics in Q3 2022 and held it in 3 quarters.
  • Wealth Alliance Advisory Group's Vivos Therapeutics position peaked at $23K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2023.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2023, filed 13 Jul 2023.